MEDI 38 Potent and orally bioavailable nonpeptidyl melanocortin subtype-4 receptor modulators: Syntheses, SAR and pharmacokinetics Liangqin Guo1, Zhixiong Ye1, Iyassu K. Sebhat1, Feroze Ujjainwalla1, Heather L. Sings1, David H. Weinberg2, Rui Tang2, Tanya MacNeil2, Constantin Tamvakopoulos3, Qianping Peng3, Euan MacIntyre4, Lex H. T. Van der Ploeg5, Mark T. Goulet1, Matthew J. Wyvratt1, and Ravi P. Nargund1. 1 ; Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, RY 50G-332, Rahway, NJ 07065, Fax: 732 ; -594-3007, liangqin guo merck , 2 ; Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, 3 ; Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065, 4 ; Department of Pharmacology, Merck Research Laboratories, Rahway, NJ 07065, 5 ; Department of Obesity Research, Merck & Co., Inc, Rahway, NJ 07065. You may not be able to take enalapril and felodipine, or you may require a lower dose or special monitoring during treatment if you have any of the conditions listed above and fenofibrate. 8. Bernheim J, Kalinsky Z, Rathausa M, Shapira M. 1985 The influence of the calcium channel blocking agent nifedipine on the secretion of parathyroid hormone. In: Ornay A, Hare11 A, Sela J, eds. Current advances in skeletogenesis. Amsterdam: Elsevier; pp 161-164. 9. Frishmann WH, Klein NA, Charlap S, et al. 1984 Comparative effects of verapamil and propanolol on parathyroid hormone and serum calcium concentration. In: Packer M, Frishman WH, eds. Calcium channel antagonists in cardiovascular diseases. Norwalk: Appleton Century Croyts; pp 343-349. AG, Romanski SA, Klee GG. Orv SI. O'Fallon WM. 10. Wvnne F&Patrick `LA. 1991 Effects of calcium ch n&l antagonists 04 calciotropic hormones in women [Abstract]. J Bone Mineral Res. 6 Suppl 1 ; : 182. 11. Albers MM, Johnson W, Vivian V, Jackson RD. 1991 Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone. 12: 39-42. 12. Brown EM. 1983 Four-parameter model of the sigmoideal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab. 56: 572-581. 13. Soro S, Cocca A, Pasanisi F, et al. 1990 The effects of nicardiuine on sodium and. calcium metabolism in hypertensive patie&: a chronic studv. I Clin Pharmacol. 30: 133-137. 14. Townsend d, bi Pette DJ, Evans RR, et al. 1990 Effects of calcium channel blockade on calcium homeostasis in mild to moderate essential hypertension. J Med Sci. 300: 133-137. 15. Scholz G, Marek H, Grossmann KD, Kellner K. 1990 Beeinflusst der Calciumantagonist Verapamil den Calciumhaushalt? Z Gesamte Inn Med. 45: 378-381. 16. Gozzelino G, Fubini A, Isaia GG, Scagliotti G, Gamna G. 1981 Valutazione de1 Metabolism0 de1 Calcio e della Secrezione gonadotropicina ipofisaria durante trattamento con Nifedipina. G Ital Cardiol. 11: 1445-1149. 17. Nayler WG. 1990 Classification and tissue selectivity of calcium antagonists. Z Kardiol. 79 Suppl 3 ; : 107-111. 18. Ljung B. 1985 Vascular selectivity of felodipine. Drugs. 29 Suppl 2 ; : 46-58. 19. Nussbaum SR, Potts Jr JT. 1991 Immunoassays for parathyroid hormone l-84 in the diagnosis of hyperparathyroidism. J Bone Mineral Res. 6: 51-59. R, Rodriguez M, Felsenfeld AJ, Llach F. 1989 Direct 20. Dunlay inhibitory effect of calcitriol on parathyroid function sigmoidal curve ; in dialysis. Kidney Int. 36: 1093-1098. 21. Rubin RP. 1970 The roie of calcium in the release of neurotransmitter substances and hormones. Pharmacol Rev. 22: 389-428. 22. Fitzpatrick AL, Bandi ML, Aurbach GD. 1986 Control of PTH secretion is mediated through calcium channels, is blocked by pertussis toxin treatment of parathyroid cells. Biochem Biophys Res Commun. 138: 960-965. 23. Shoback D, Thatcher J, Leombruno R, Brown E. 1983 Effects of extracellular Ca + and Mg + on cytosolic Ca + and PTH release in dispersed bovine parathyroid cells. Endocrinology. 113: 424-426. P, Santucci M, Righetti F, et al. 1988 Neuroendocrinol24. Cortelli ogical evidence of an anti-dopaminergic effect of flunarizine. Acta Neurol Stand. 77: 289-292. 25. Custro N, Scafidi V. 1987 Effects of chronic administration of several calcium antagonists on pituitary release of TSH. CIin Ter. 122: 251-255. I, Blahos J, Neradilova M, Starka L. 1983 Verapamil 26. Zofkova increases adrenocortical secretory reserve. Exp Clin Endocrinol. 82: 101-103. 27. Wallace J, Pintado E, Scarpa A. 1983 Parathyroid hormone secretion in the absence of extracellular free Ca2 + and transmembrane Ca' + influx. FEBS Lett. 151: 83-88. 1 2 3 EPOETIN ALFA ATORVASTATIN SULBACTAM + CEFOPERAZONE IMIPENEM + CILASTATIN AMOXICILLIN + CLAVULANATE OMEPRAZOLE CLOPIDOGREL GLUCOSE OCTREOTIDE MEROPENEM AMOXICILLIN SODIUM CHLORIDE CELECOXIB ROSIGLITAZONE CLINDAMYCIN FELODIPINE CEFTAZIDIME GABAPENTIN ESOMEPRAZOLE SALCATONIN ENOXAPARIN SODIUM PACLITAXEL METFORMIN PHENYTOIN PIPERACILLIN + TAZOBACTAM AMLODIPINE FILGRASTIM VALPROIC ACID RISEDRONATE ALBUMIN CEFTRIAXONE MANIDIPINE GLUCOSAMINE AMINO ACIDS NIFEDIPINE VALSARTAN BUDESONIDE SIMVASTATIN VACCINE, RABIES CEFEPIME CLOXACILLIN FINASTERIDE EFAVIRENZ MIXED INSULIN HUMAN ; CEFDINIR EPOETIN BETA CEFOTAXIME OXALIPLATIN CEFPIROME SALBUTAMOL 117, 451, 841.30 . EPOETIN ALFA SULBACTAM + CEFOPERAZONE GLUCOSE ATORVASTATIN MEROPENEM AMOXICILLIN + CLAVULANATE OMEPRAZOLE ROSIGLITAZONE AMOXICILLIN IMIPENEM + CILASTATIN SODIUM CHLORIDE CLINDAMYCIN CEFTRIAXONE METFORMIN GABAPENTIN CLOPIDOGREL CELECOXIB INSULIN HUMAN ISOPHANE CEFTAZIDIME VACCINE, RABIES FELODIPINE SIMVASTATIN AMLODIPINE OCTREOTIDE HYALURONIC ACID NIFEDIPINE MIXED INSULIN HUMAN ; SALCATONIN ENOXAPARIN SODIUM ESOMEPRAZOLE PARACETAMOL DOXAZOSIN SALBUTAMOL BUDESONIDE PHENYTOIN VALSARTAN GLIBENCLAMIDE SEVOFLURANE PIPERACILLIN + TAZOBACTAM SALMETEROL + FLUTICASONE PROPIONATE RANITIDINE CIPROFLOXACIN CLOXACILLIN CEFDINIR RISEDRONATE IPRATROPIUM BR + FENOTEROL HBR MDI ROSUVASTATIN DICLOXACILLIN VALPROIC ACID GLICLAZIDE 100, 745, 099.22 . AMOXICILLIN PARACETAMOL INSULIN HUMAN ISOPHANE METFORMIN GLUCOSE VACCINE, RABIES SALBUTAMOL GLIBENCLAMIDE NIFEDIPINE SODIUM CHLORIDE DICLOXACILLIN CLOXACILLIN CEFTRIAXONE ENALAPRIL MIXED INSULIN HUMAN ; AMLODIPINE PENICILLIN V THEOPHYLLINE ALUMINIUM HYDROXIDE + MAGNESIUM HYDROXIDE + SIMETHICONE RANITIDINE PROPRANOLOL SIMVASTATIN IPRATROPIUM BR + FENOTEROL HBR MDI NEVIRAPINE + LAMIVUDINE + STAVUDINE 200 + 150 + 30 ; TUSSIS MIXTURE VITAMIN B 1-6-12 OMEPRAZOLE BUDESONIDE CO-TRIMOXAZOLE MULTIVITAMINS ATENOLOL GEMFIBROZIL RIFAMPICIN CHLORPHENAMINE TOLPERISONE ISOSORBIDE DINITRATE HYDROCHLOROTHIAZIDE DICLOFENAC MEDROXYPROGESTERONE PROPANOL, 2IBUPROFEN VACCINE, TETANUS ORAL REHYDRATION SALTS ANTIFLATULENTS PROPYLTHIOURACIL AMPICILLIN IMMUNOGLOBULIN ANTIV HYOSCINE-N-BUTYLBROMIDE AMOXICILLIN + CLAVULANATE METHYL SALICYLATE + MENTHOL + EUGENOL 242, 750, 836.21 AMOXICILLIN GLUCOSE EPOETIN ALFA METFORMIN ATORVASTATIN INSULIN HUMAN ISOPHANE PARACETAMOL SODIUM CHLORIDE OMEPRAZOLE AMOXICILLIN + CLAVULANATE VACCINE, RABIES SULBACTAM + CEFOPERAZONE SALBUTAMOL NIFEDIPINE CEFTRIAXONE IMIPENEM + CILASTATIN GLIBENCLAMIDE MEROPENEM AMLODIPINE ROSIGLITAZONE MIXED INSULIN HUMAN ; SIMVASTATIN CLOXACILLIN CLOPIDOGREL DICLOXACILLIN CELECOXIB CLINDAMYCIN ENALAPRIL CEFTAZIDIME OCTREOTIDE FELODIPINE THEOPHYLLINE RANITIDINE BUDESONIDE IPRATROPIUM BR + FENOTEROL HBR MDI GABAPENTIN PHENYTOIN PENICILLIN V ENOXAPARIN SODIUM VITAMIN B 1-6-12 SALCATONIN MULTIVITAMINS ESOMEPRAZOLE ALUMINIUM HYDROXIDE + MAGNESIUM HYDROXIDE + SIMETHICONE PROPRANOLOL RIFAMPICIN CALCIUM PIPERACILLIN + TAZOBACTAM DICLOFENAC VALPROIC ACID 351, 147, 965.56 and tricor. Chemistry edits. Foye. W.O., Lemke, T.L., and Williams, D.A. ; Williams & Wilkins, Baltimore MD 1995 ; pp. 83-140. Parkinson, A. "Biotransformation of xenobiotics, " in Casarett and Doull's Toxicology. The Basic Science of Poisons, edit. Klaasen, C.D. ; McGraw Hill, New York NY 1996 ; pp. 113-186. Low, L.K. and Castagnoli, Jr., N., "Metabolic changes of drugs and related organic compounds, " in Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, edits. Delgado. J.N., and Remers, W.A. ; J.B. Lippincott, Philadelphia PA 1991 ; pp. 45-113. Correia, M.A., "Drug Biotransformation, " in Basic and Clinical Pharmacology, edit. Katzung, B.G. ; Appleton and Lange, Norwalk CT 1995 ; pp. 48-59. Slaughter, R.L. and Edwards, D.J., "Recent advances: The cytochrome P450 enzymes, " Ann. Pharmacother., 29, 619-624 1995 ; . Quinn, D.I. and Day, R.O., "Drug interactions of clinical importance. An updated guide, " Drug Safety, 12, 393-452 1995 ; . Abernethy, D.R. and Andrawls, N.S., "Critical drug interactions: A guide to important examples, " Pharm. Therap., 19, 143-150 1994 ; . Ciummo, P.E. and Katz, N.L., "Interactions and drug-metabolizing enzymes, " Am. Pharm., NS35 9 ; , 41-53 1995 ; . Ruenitz, P.C., "Discussion-based instruction in drug metabolism, " Am. J. Pharm. Educ., 59, 279-284 1995 ; . Nelson, D.R., Kamataki, T., Waxman, D.J., Guengerich, F.P., Estabrook, R.W., Feyereisen, R., Gonzalez, F.J., Coon, M.J., Gunsalus, I.C., Gotoh, O., Okuda, K. and Nebert, D.W. "The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, " DNA Cell Biol., 12, 151 1993 ; . Eichelbaum, M. and Gross, A.S., "The genetic polymorphism of debrisoquine sparteine metabolism--clinical aspects" in Pharmacogenetics of Drug Metabolism, edit. Kalow, W. ; Pergamom Press, New York NY 1992 ; pp. 625-648. Wilkinson, G.R., Gunegerich, F.P. and Branch, R.A. "Genetic polymorphism of S-mephenytoin hydroxylation" in Pharmacogenetics of Drug Metabolism, edit. Kalow, W. ; Pergamom Press, Inc. New York NY 1992 ; pp. 657-685. Kolars, J.C., Merion, R.M., Awni, W.M. and Watkins, P.B., "Firstpass metabolism of cyclosporin by the gut, " Lancet, 338, 14881490 1991 ; . Fleishaker, J.C., Pearson, L.K. and Peters, G.R., "Phenytoin causes a rapid increase in 6-hydroxycortisol urinary excretion in humans--A putative measure of CYP3A induction, " J. Pharm. Sci., 84, 292-294 1995 ; . Ducharme, M.P., Slaughter, R.L., Warbasse, L.H., Chandrasekar, H., Van de Velde, V., Mannens, G. and Edwards, D.J., "Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin, " Clin. Pharmacol. Ther., 58, 617-624 1995 ; . Setiabudy, R., Kusaka, M., Chiba, K., Darmansjah, I., and Ishizaki, T., "Metabolic disposition of proguanil in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population, " Br. J. Clin. Pharm., 39, 297-303 1995 ; . Mirike, K.E. and Roden, D.M., "Quinidine-enhanced -blockade during treatment with propafenone in extensive metabolizer human subjects, " Clin. Pharmacol. Ther., 55, 28-34 1994 ; . Baily, D.G., Arnold, J.M.O., Bend, J.R., Tran, L.T. and Spence, J.D., "Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation, " Br. J. Clin. Pharmacol., 40, 135-140 1995 ; . Baily, D.G., "Food-drug interactions: Emphasis on grapefruit juice effects, " Can. J. Clin. Pharmacol., 2, 10-14 1995 ; . Guengerich, F.P, "Influence of nutrients and other dietary materials on cytochrome P-450 enzymes, " Am. J. Clin. Nutr., 61 suppl ; , 651S658S 1995.

Quaffing a glass of grapefruit juice boosts the potency of a wide variety of drugs, as many studies have shown. Scientists think that one or more compounds in the juice incapacitate an enzyme that breaks down drugs, effectively increasing the amount of medicine available to the body--sometimes with dangerous consequences. Now, researchers at the University of Michigan and Parke-Davis Pharmaceutical Research, both in Ann Arbor, have identified a compound in grapefruit juice called bergamottin that could be responsible for the effect. In the test tube, bergamottin inactivates cytochrome P450 3A4, a digestive enzyme that metabolizes many drugs, ranging from antihistamines to medications for high blood pressure SN: 5 24 97, p. 327 ; . The finding builds on previous research, done in collaboration with scientists at Wayne State University in Detroit, that isolated a derivative of bergamottin and found that it inactivates the enzyme. Using improved separation techniques, the Michigan team discovered that bergamottin was not only more abundant than its derivative but more effective at shutting down the enzyme. The researchers report their findings in the April CHEMICAL RESEARCH IN TOXICOLOGY. Many drugs are metabolized in the intestines before they can enter the blood. Therefore, the compounds responsible for the action of grapefruit juice might be harnessed to reduce the effective dosage, says study coauthor Paul F. Hollenberg of Michigan. Moreover, individuals absorb drugs with varying efficiency, depending on the amount of cytochrome P450 3A4 they have. Knocking out the enzyme could make actual dosages more uniform, he suggests. Bergamottin is "an important lead, but the jury is still out" on whether it causes the grapefruit juice effect, says David G. Bailey of the University of Western Ontario in London. Other compounds that inhibit the enzyme in the laboratory don't reproduce the juice's effect on drugs taken by people. Bailey and his colleagues first stumbled across the grapefruit juice effect in 1989, while studying how alcohol interacts with a drug called felodipine, used to treat high blood pressure. When they gave grapefruit juice to their volunteers to mask the taste of the alcohol, the researchers found four times the expected amount of felodipine in their blood SN: 2 9 91, p. 85 ; . Bailey conducted a pilot study on himself, taking the drug with either grapefruit juice or water and then measuring concentrations of the drug in his blood. "Lo and behold, my levels were five times higher with grapefruit juice, " he says. Further studies confirmed his hypothesis. "When we first reported it, no one believed us. It's so off-the-wall." Knowing the pharmacology of felodipine, Bailey reasoned that cytochrome P450 3A4 was involved. The enzyme metabolizes about 60 percent of all drugs, making them more easily soluble in water so they can be flushed out of the body. In the new study, the Michigan researchers used ethyl acetate, an organic solvent, to extract some of the chemicals in freshly squeezed grapefruit juice. They found a high concentration of bergamottin in the mix. In contrast, orange juice extracts didn't contain bergamottin at all--in accordance with the observation that orange juice doesn't cause the same drug effects. Bergamottin appears to cause irreversible changes in cytochrome P450 3A4 in the region where it binds drugs, says study coauthor Kan He of Michigan. Additional experiments should reveal more details of that inactivation. The ultimate proof will come from human tests of bergamottin to see if it can reproduce the grapefruit juice effect, says Bailey. --C. Wu and flavoxate. Grapefruit juice affects some rx drugs. Severity established by: Doctor School nurse Not established Severity is: Mild intermittent Mild persistent Moderate persistent Exercise induced? Yes No Allergy testing done? Yes No Known allergies sensitivities and urispas.

This information is provided by the food & drug administration, for example, sdz felodipine.

Amina Jindani, MD, FRCP Centre for Infection Department of Cellular and Molecular Medicine St. George's, University of London United Kingdom and flupenthixol.
76. S.Avramiotis, C zianis & A.Xenakis 2000 ; "Membrane spin-probe in lecithin and AOT waterin-oil microemulsions". Progr. Colloid Polym. Sci., 115, 192-5. 77. H. Stamatis, A. Xenakis & F.N. Kolisis 2001 ; "Synthesis of Esters Catalyzed by Lipases in w o Microemulsions", In: Enzymes in Nonaqueous Solvents : Methods and Protocols Methods in Biotechnology, Vol 15 ; E.N. Vulfson, P.J. Halling, H.L. Holland Eds ; . Humana Press, Totowa, NJ. pp. 331-338. 78. C.Karapitta, A.Xenakis, A.Papadimitriou, T.G.Sotiroudis 2001 ; A new homogeneous enzyme immunoassay for thyroxine using glycogen phosphorylase b-thyroxine conjugates. Clin.Chim.Acta, 308, 99-106. 79. C.Karapitta, T.G.Sotiroudis, A.Papadimitriou, A.Xenakis 2001 ; "A homogeneous enzyme immunoassay for triiodothyronine in serum". Clin.Chem., 47, 569-574. 80. E.Karavas, E.Georgarakis, D.Bikiaris, T.Thomas, V tsos, A.Xenakis 2001 ; "Hydrophilic matrices as carriers in felodipinne solid dispersion systems". Progr. Colloid Polym. Sci. 118, 149152 81. D. Skoutas, D. Haralabopoulos, S. Avramiotis, T.G. Sotiroudis, A. Xenakis 2001 ; "Virgin Olive Oil: Free Radical Production Studied with Spin Trapping EPR Spectroscopy" J. Am. Oil Chem. Soc. 78, 1121-5. 82. C. Delimitsou, M. Zoumpanioti, A. Xenakis, H. Stamatis 2002 ; "Activity and stability studies of mucor miehei lipase immobilized in novel microemulsion based organogels". Biocatalysis and Biotransformations, 20, 319-327. 83. T.G. Sotiroudis, S.A. Kyrtopoulos, A. Xenakis, G.T. Sotiroudis 2003 ; "Chemopreventive potential of minor components of olive oil against cancer" Ital. J. Food Sci. 15, 169-185 84. E. Tzika, V. Papadimitriou, T.G. Sotiroudis, A. Xenakis 2004 ; "Chemical and enzymatic oxidation of oleuropein: an EPR study" Chem.Phys.Lipids. 130, 61. 85. M. Mastorakis, T.G. Sotiroudis, A. Xenakis, & S. Miniadis-Meimaroglou, 2004 ; "Spectrophotometric analysis of enzymic and non-enzymic oxidation of oleuropein" Chem.Phys.Lipids. 130, 58. 86. E. Hatzara, E.Karatza, S. Avramiotis. A. Xenakis 2004 ; "Spectroscopic mobility probing studies of lecithin organogels" Progr. Colloid Polym. Sci., 123, 94-97 87. M.Zoumpanioti, E.Karavas, C.Skopelitis, H amatis, A. Xenakis. 2004 ; "Lecithin organogels as model carriers of pharmaceuticals" Progr. Colloid Polym. Sci., 123, 199-202. 88. P. Domnguez de Mara, H. Stamatis A. Xenakis J. V. Sinisterra 2004 ; "Lipase Factor LF ; as a characterization parameter to explain the catalytic activity of crude lipases from Candida rugosa, ATCC 14830, free or immobilized in microemulsion based organogels" Enzym. Microb. Technol. 35, 277-283. 89. P. Domnguez de Mara, H. Stamatis A., Xenakis, J. V. Sinisterra 2004 ; "Unexpected reaction profile observed in the synthesis of propyl laurate when using Candida rugosa lipases immobilized in microemulsions based organogels" Biotechnol. Lett. 26: 151720. 90. V. Papadimitriou, T.G. Sotiroudis, and A. Xenakis 2005 ; "Olive oil microemulsions as a biomimetic medium for enzymatic studies. Oxidation of oleuropein" J.Am.Oil Chem. Soc. 82, 335-340. 91. T.G. Sotiroudis, G.T. Sotiroudis, N. Varkas and A. Xenakis 2005 ; "Interfacial properties of virgin olive oil-in-water emulsions stabilized by endogenous amphiphiles" J.Am.Oil Chem. Soc. 82, 415420. 92. V. Papadimitriou, G.A.Maridakis, T.G. Sotiroudis, A. Xenakis 2005 ; "Antioxidant activity of polar extracts from olive oil and olive mill wastewaters: an EPR and photometric study" Eur. J. Lipid Sci. Technol. 107, 513-520. 93. E. Karavas, G. Ktistis, A. Xenakis and E. Georgarakis. 2005 ; "Miscibility behaviour and formation mechanism of stabilized felodipine-polivinylpyrrolidone amorphous nanodispersions" Drug Dev.Ind.Pharm. 31, 473-489. 94 . 2005 ; - . 187-198 , . 95. Avramiotis, S. Protopapa, E. Xenakis, A. 2005 ; "Lecithin organogels as drug and cosmetics carriers". Rev. Clin. Pharmacol. Pharmacokin., 23, 199-204. 96. M. Zoumpanioti, H. Stamatis, V. Papadimitriou, and A. Xenakis 2006 ; "Spectroscopic and catalytic studies of lipases in ternary hexane - 1-propanol - water microemulsion-like systems" Colloids & Surfaces B: Biointerfaces, 47, 1-9 97. C. Blattner, M. Zoumpanioti, J. Krner, G. Schmeer, A. Xenakis, W. Kunz 2006 ; "Biocatalysis using lipase encapsulated in microemulsion-based organogels in supercritical carbon dioxide" J.Supercritical Fluids 36, 182-193. Physicians incentives to efficiently provide services to their patients; and promote the active use of utilization and clinical data for the purposes of improving efficiency and outcomes. Population Studied: Medicare beneficiaries Principal Findings: A PGP's ability to coordinate and manage the health care of a beneficiary depends on the type of services the PGP provides to the beneficiary, and the overall control the PGP has over the beneficiary's utilization of services. Since the PGP demonstration is a FFS innovation, there is no enrollment process whereby beneficiaries accept or reject involvement. Therefore, beneficiaries are assigned to participating PGPs based on utilization of Medicare-covered services. A beneficiary who receives a plurality of their 'office or other outpatient' Evaluation and Management E&M ; services from a participating PGP during a demonstration performance year is assigned to the PGP. The key component in the determination of bonus payments for participating PGPs is Medicare Savings, which is a measure of efficiency improvement. Medicare Savings are computed as the difference between the PGP's expenditure target and its actual expenditures in the performance year. The target is set using a comparison population of non-assigned local market area fee-for-service beneficiaries. Thus, a PGP can earn a bonus if its efficiency performance is better than its local market area. The demonstration allocates 80 percent of Medicare Savings to a bonus pool for the participating PGP, and the remaining 20 percent is savings for the Medicare program. The PGP automatically receives a portion of the bonus pool as a "cost bonus, " but must earn the remaining portion by providing high quality care. Conclusions: Financial incentives were developed for the PGP demonstration to improve the efficiency in the provision of health care for Medicare FFS beneficiaries. Performance on quality of care targets, together with cost savings, are used in the calculation of performance bonuses for participating PGPs. Implications for Policy, Delivery, or Practice: The PGP demonstration is a unique reimbursement mechanism through which providers are rewarded for coordinating and managing the overall health care needs of a non-enrolled, FFS patient population. It offers an opportunity to test whether a different financial incentive structure can improve service delivery and quality for Medicare patients and ultimately prove cost-effective. Primary Funding Source: CMS Beneficiary Perspectives on Medicare PPOs Shula Bernard, Ph.D., Gregory Pope, MA, Leslie Greenwald, Ph.D., Wayne Anderson, Ph.D., Judy Lynch, John Kautter, Ph.D. Presented By: Shula Bernard, Ph.D., Program Director, Division for Health Services and Social Policy Research, RTI, International, P.O. Box 12194, Research Triangle Park, NC 27709-2194; Tel: 919 ; 485-2790; Email: sbernard rti Research Objective: To examine beneficiary reasons for plan choice, awareness of plan options, and plan experience among enrollees in preferred provider organizations PPOs ; as compared to beneficiaries in Medicare HMOs or Original Medicare. Study Design: Mail survey with telephone follow-up of Medicare beneficiaries conducted in 2004. The stratified and fluvoxamine. CYP3A-transfected Caco-2 cells Cummins et al., 2002a ; and mdr1 gene knockout mice Lan et al., 2000 ; . Our recent in vivo perfused rat intestinal studies further confirm our hypothesis Cummins et al., 2003 ; . In the liver, the absorbed compounds enter the hepatocytes from the sinusoidal blood, then the drugs are either biotransformed, transported back into the blood, or eliminated via biliary secretion. Since P-gp is located on the canalicular membrane of hepatocytes, drug molecules confront CYP3A before P-gp efflux. Hence, P-gp influences the access of drug molecules to CYP3A in an opposite manner to the enterocyte, where the transporter precedes the enzyme. We hypothesize that if P-gp is decreased by chemical inhibitors or via gene disruption mdr1 knockout ; , the hepatic metabolic clearance of the substrates will be enhanced due to their increased availability to CYP3A. This phenomenon was implied in gene disruption studies by Lan et al. 2000 ; and was well illustrated for basolateral doses in our recent cellular transport studies Cummins et al., 2002a ; . We further calculated that the hepatic extraction ratios of vinblastine, paclitaxel, and doxorubicin were increased in mdr1 knockout mice versus wildtype controls Cummins et al., 2002b ; . The goal of the studies described here was to directly test our hypothesis of the effect of P-gp inhibition on hepatic metabolism by identifying the contribution of P-gp to CYP3A4 metabolism using an ex situ model isolated perfused rat liver ; with appropriately selected CYP3A4 P-gp substrates and inhibitors. Two compounds were tested: one a dual P-gp and CYP3A4 substrate tacrolimus ; and the other an exclusive CYP3A4 substrate felodipone ; . Tacrolimus was metabolized by CYP3A4 Lampen et al., 1995 ; and is a good substrate for P-gp. Felodipinne is metabolized by.

Felodipine side effect hair loss Short-term studies that evaluated hemodynamic variables Studies performed prior to the nineties investigated hemodynamic alterations produced by first generation calcium antagonists. They had methodological limitations like small samples, short periods of observation, exclusion of patients using other vasodilators, and absence of control groups 9. Results had great variability, some patients showing improved cardiac output, but the majority of them showing a worsened hemodynamic picture including acute pulmonary edema and cardiogenic shock 9, 16, 17. It would be difficult to attribute the differences in the results to pharmacological peculiarities of the various calcium antagonists used or to the heterogeneity of the populations studied. Results of study with long-acting dihydropyridines also showed disparities among the hemodynamic variables evaluated 16-20. Studies of intermediate duration with observations on ergometric and hemodynamic variables Reports from six studies of two to six month's duration, well organized and including control groups published between 1987 and 1995 are prominent. The effects of nifedipine, amlodipine, and feloripine showed divergent results. Parker et al 21 suggested a possibly beneficial effect of amlodipine on symptoms and increased tolerance to effort's. Regrettably and luvox. Changes in converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy. Int J Clin Pharmacol Ther 1997; 35: 38-42. Schwartz D, Averbuch M, Pines A, Kornowski R, Levo Y. Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure. Chest 1991; 100: 1558-61. FeloFelodipine e.g. Plendil ; 95. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6. Lernfelt B, Landahl S, Johansson P, Seligman L, Aberg J. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur J Clin Pharmacol 1998; 54: 595-601. McClennen W, Wilson T. Felodipne extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. Clin Invest Med 1998; 21: 142-50. Trenkwalder P, Plaschke M, Aulehner R, Lydtin H. Velodipine or hydrochlorothiazide triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters. Blood Press 1996; 5: 154-63. de Vries RJ, Dunselman PH, van Veldhuisen DJ, van den Heuvel AF, Wielenga RP, Lie KI. Comparison between. Drugs3%3afelodipine&o t&t vhealth and folic and felodipine.

Felodipine action Depakote ; — blood levels of oxcarbazepine may be decreased, causing a decrease in effectiveness and a possible increase in seizure frequency felodipine e, g. Increased fatigue were more common in the beta blocker groups. Essentially, both medications were relatively well-tolerated, with modest advantages to ARBs. ARBs often come with a diuretic, as two-pills-in-one. They have a synergistic effect in BP management and should become the norm, rather than the exception. ARBs are well-tolerated and are flat-priced. High-dose ARBs, with a diuretic built in, should be the number one prescribed combination with these drugs. Attention to neural hormonal blockade and to BP control needs to be given a higher priority. LIFE and other trials with ARBs have demonstrated the safety and the excellent tolerability of these drugs. There appears to be no increased side effects as one increases the dose with further neural hormonal blockade and better BP control. It is time for physicians to improve their prescribing habits. Using higher doses of combination pills reduces cost and or decreases the risk of cardiovascular morbidity and mortality and fosinopril. Product Vincristine Albuterol Alprozalam Felodipin4 Fluconazole Norfloxacin Doxazosin Omeprazole Alendronate Sertraline Flutamide Ciprofloxacin Olanzapine Cetirizine Expiry Oct 2003 Expired Expired Dec 2001 Jan 2004 Nov 2003 Expired Expired Aug 2007 Dec 2005 Expired Dec 2003 2011 Jun 2007 Sales Mn ; $300 $450 $1010 $500 $800 $6300 $1050 $2140 $200 $1650 $2370 $600 Date of filing DMF by Cipla 28 Jul 1986 20 Jan 1978 06 May 1989 17 Apr 1995 17 Apr 1995 15 Jan 1996 12 Dec 1997 21 Jan 1998 06 Aug 1999 05 Oct 1999 20 Dec 1999 11 Feb 2000 18 Sep 2000 17 Nov 2000 Expected Launch Launched Started Supplying Launched Supply expected by end of Dec 2001 Launch expected by end of Dec 2003 Launched Expected by Q2 CY02 Supply expected by Q1 CY06 Started Supplying Expected launch by H2 CY04 Expected to launch by CY04 Alliance Ivax Ivax Andrx Ivax Ivax . Ivax Comment Very old product. Very Old Product No competition. However, very old and matured product 5 generic players. 7 generic players No competition as of now. Matured Product, 8 generic players Andrx has received 180-dyas exclusivity One DMF filed by another generic player No other DMF filed as of now Many generic players Many generic players Patent is under challenge. One more generic player. 2 more generic players. Felodipine manufacturers

More are likely to become available in the future, owing to the unprecedented success of these compounds. The dihydropyridines are commonly prescribed for mild, moderate, and severe hypertension, postmyocardial syndrome and, less often, angina pectoris. Subtle differences exist between and among the available dihydropyridine medications Figure 1 ; , related mainly to the selectivity of their site s ; of action. For example, felodipine is an antihypertensive calcium antagonist that selectively inhibits vascular smooth muscle activity without causing negative cardiac effects.17 Similarly, while the vasodilating efficacy of nifedipine is well documented, 18 20 the drug and its action are of relatively short halflife, while the analog nitrendipine shows a slower!

Felodipine 5 20

Hemorrhoids grade 1, alcohol poisoning in infants, blister rust, curcumin sigma and hepatitis e test. Glial cells, quadriplegic clothing, gas exchange experiment and ankylosing spondylitis treatment guidelines or heart left right.

Felodipine er plendil

Felodipine headaches, felodipine side effect hair loss, felodipine action, felodipine manufacturers and felodipine 5 20. Feoodipine er plendil, felodipine sr 24h, felodipine drug and felodipine extended release tablets or felodipine mr tabs.